Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
- PMID: 11756187
- DOI: 10.1182/blood.v99.1.319
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
Abstract
In clinical trials, the tyrosine kinase inhibitor STI571 has proven highly effective in reducing leukemic cell burden in chronic myeloid leukemia (CML). The overall sensitivity of CML CD34(+) progenitor cells to STI571 and the degree to which cell death was dependent on cell cycle status were determined. Stem cells (Lin(-)CD34(+)) from the peripheral blood of patients with CML in chronic phase and from granulocyte-colony-stimulating factor-mobilized healthy donors were labeled with carboxy-fluorescein diacetate succinimidyl diester dye to enable high-resolution tracking of cell division. Then they were cultured for 3 days with and without growth factors +/- STI571. After culture, the cells were separated by fluorescence-activated cell sorting into populations of viable quiescent versus cycling cells for genotyping. For healthy controls, in the presence of growth factors, STI571 affected neither cell cycle kinetics nor recovery of viable cells. In the absence of growth factors, normal cells were unable to divide. For CML samples, in the presence or absence of growth factors, the response to STI571 was variable. In the most sensitive cases, STI571 killed almost all dividing cells; however, a significant population of viable CD34(+) cells was recovered in the undivided peak and confirmed to be part of the leukemic clone. STI571 also appeared to exhibit antiproliferative activity on the quiescent population. These studies confirm that CML stem cells remain viable in a quiescent state even in the presence of growth factors and STI571. Despite dramatic short-term responses in vivo, such in vitro insensitivity to STI571, in combination with its demonstrated antiproliferative activity, could translate into disease relapse after prolonged therapy.
Similar articles
-
[A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Dec;13(6):1004-9. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005. PMID: 16403268 Chinese.
-
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.Blood. 2003 Jun 15;101(12):4701-7. doi: 10.1182/blood-2002-09-2780. Epub 2003 Feb 6. Blood. 2003. PMID: 12576334
-
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.Blood. 2002 May 15;99(10):3792-800. doi: 10.1182/blood.v99.10.3792. Blood. 2002. PMID: 11986238
-
[Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].Nihon Yakurigaku Zasshi. 2003 Dec;122(6):482-90. doi: 10.1254/fpj.122.482. Nihon Yakurigaku Zasshi. 2003. PMID: 14639002 Review. Japanese.
-
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.Lancet Oncol. 2000 Dec;1:207-11. doi: 10.1016/s1470-2045(00)00149-2. Lancet Oncol. 2000. PMID: 11905636 Review.
Cited by
-
Function of oncogenes in cancer development: a changing paradigm.EMBO J. 2013 May 29;32(11):1502-13. doi: 10.1038/emboj.2013.97. Epub 2013 Apr 30. EMBO J. 2013. PMID: 23632857 Free PMC article. Review.
-
An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments.Front Bioeng Biotechnol. 2020 May 28;8:523. doi: 10.3389/fbioe.2020.00523. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32548108 Free PMC article.
-
Tracking of Normal and Malignant Progenitor Cell Cycle Transit in a Defined Niche.Sci Rep. 2016 Apr 4;6:23885. doi: 10.1038/srep23885. Sci Rep. 2016. PMID: 27041210 Free PMC article.
-
Recent advances in understanding chronic myeloid leukemia: where do we stand?Fac Rev. 2021 Apr 1;10:35. doi: 10.12703/r/10-35. eCollection 2021. Fac Rev. 2021. PMID: 33977288 Free PMC article. Review.
-
Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest.Leuk Res Treatment. 2012;2012:861301. doi: 10.1155/2012/861301. Epub 2012 Feb 23. Leuk Res Treatment. 2012. PMID: 23213550 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical